aleniglipron
GSBR-1290 Small Molecule Target: GLP-1R
Structure Therapeutics Inc.
Most recent annual filing: 2026-02-26
Pipeline (5 active programs)
Technology platforms
Structure-Based Drug Discovery Platform · Schrödinger
GPCR-focused structure-based drug discovery platform combining 3D protein structure visualization, computational chemistry, and physics-based methods in collaboration with Schrödinger. Targets GPCRs in metabolic, cardiovascular, and pulmonary diseases, enabling design of oral small molecule therapeutics against targets historically limited to peptides or biologics.
Targets: GPCRs
Discontinued (1)
- ANPA-0073 — undisclosed · decided not suitable for selective weight loss; deprioritized in favor of other discovery stage APJ receptor agonists
Biotech Distilled coverage (2)
- 2026-05-08 UPDATE: Structure Therapeutics (GPCR) - The 16.3% Print and the Quiet ATM Upsize 🔒 Paid
- 2026-04-28 Structure Therapeutics (GPCR) - Scientific Deep Dive for Aleniglipron and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.